OptiNose — Investor Presentation (March 2022)
30 slides from OptiNose's investor presentation, Mar 14, 2022
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n Ma r c h 1 4 , 2 0 2 2
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this
Slide 3: Our Growth Strategy
3 Our Growth Strategy Continue to commercialize XHANCE in the ENT and allergy specialty segments in the U.S. Continue clinical development of XHANCE for the treatment of chronic sinusitis and expansion into the primary care segment to broaden our market opportunity Seek additional development
Slide 4: Our Pipeline
Our Pipeline Basalt | chin | Pisses | ose2 | ruaea | non | ae (Nasal Polyps) XHANCE (Chronic Sinusitis) | rwnertrarms | chy | rsset | rimez | mes | non | Approwss ONZETRA® XSAIL® (Migraine) Licensed to Currax Orexia a Centessa Company (Orexin Agonists) 4 optinose_
Slide 5: Commercializing XHANCE as a Treatment for Nasal Polyps
Commercializing XHANCE® (fluticasone propionate) as a Treatment for Nasal Polyps
Slide 6: Annual XHANCE Net Revenue Increases of More Than 50% in 2020 and 2021
6 We Delivered Annual XHANCE Net Revenue Increases of More Than 50% in 2020 and 2021 With Our Commercial Model $30.4 $48.4 $73.7 2019 2020 2021 ($M ) XHANCE Net Revenues +52% +59% We have a sales force of approximately 100 territory managers who target over 10,000 ENT and allergy specialists and "
Slide 7: Strong New and Total Prescription Growth in 2020 and 2021
7 153.7 261.4 335.6 2019 2020 2021 We Delivered Strong New and Total Prescription Growth in 2020 and 2021 During a Challenging Period for the INS Market +28% +70% 67.4 88.6 112.7 2019 2020 2021 XHANCE NRx (in thousands) +27% +31% XHANCE TRx (in thousands) NRx for Intranasal Steroids Market decreased
Slide 8: XHANCE Market Share & Prescribers by Prescribing Frequency
8 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thir
Slide 9: Potential Value of a Chronic Sinusitis Indication
Potential Value of a Chronic Sinusitis Indication
Slide 10: What is Chronic Sinusitis (CS)
10 What is Chronic Sinusitis (CS) CS is an inflammatory disease of the paranasal sinuses that is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition
Slide 11: First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities
11 Successful Development of XHANCE as the First FDA‐approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales deployment 1 Milli
Slide 12: CS Treatment Would Increase Opportunity and Address Barriers to Prescribing
12 Successful Development of XHANCE as a Treatment for Chronic Sinusitis Would Increase Opportunity and Address Certain Barriers to Broader Prescribing that Exist Today Insurance Today, ~80% of commercial lives are in plans that cover XHANCE, but ~half require physicians to attest that they are pr
Slide 13: Our Chronic Sinusitis Development Program
Our Chronic Sinusitis Development Program
Slide 14: ReOpen1 and ReOpen2 Trial Design Summary
14 EDS Placebo 372 μg Week 24 Double Blinded Phase En d of St ud y ReOpen1 and ReOpen2 Trial Design Summary Randomized, double‐blind, EDS‐placebo‐controlled, parallel‐group, multicenter studies to evaluate efficacy and safety of XHANCE 186 μg (1 spray) and 372 μg (2 sprays) BID in subjects with CS W
Slide 15: ReOpen1 Phase 3 Trial: Design and Top-Line Results
ReOpen1 A Landmark Phase 3 Trial in the Treatment of Chronic Sinusitis: Design and Top‐Line Results
Slide 16: ReOpen1: Disposition and Baseline Characteristics
16 Re‐Open 1: Disposition and Baseline Characteristics EDS Placebo XHANCE 186 mcg XHANCE 372 mcg Subjects Randomized 112 111 109 Subjects Who Completed Study 96 102 101 Subjects Discontinuing Early* 16 9 8 Full Analysis Set 110 110 107 Evaluable subjects with NP 69 69 67 Evaluable subjects without N
Slide 17: ReOpen1: Combined Symptom Score Coprimary Endpoint
17 ReOpen‐1: Combined Symptom Score Coprimary Endpoint 1 ‐0.62 ‐1.58‡ ‐1.60‡ ‐2.0 ‐1.8 ‐1.6 ‐1.4 ‐1.2 ‐1.0 ‐0.8 ‐0.6 ‐0.4 ‐0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS‐placebo BID OPN‐375 186 μg BID OPN‐375 372 μg BID BID, twice daily; CSNS, composite symptom
Slide 18: ReOpen1: Average Percent Opacified Volume Coprimary Endpoint
18 ReOpen‐1: Average Percent Opacified Volume (Ethmoid and Maxillary) Objective CT scan Coprimary Endpoint ‐1.60 ‐5.58* ‐6.20* ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to Week 24 EDS‐placebo BID OPN‐375 186 μg BID OPN‐3
Slide 19: Illustration of APOV Improvement (186 µg BID)
19 Illustration of APOV Improvement (Patient Receiving XHANCE 186 µg BID) 6.4% Improvement Week 24Baseline Images reflect individual results and results and may not be representative of results generally.
Slide 20: Illustration of APOV Improvement (372 µg BID)
20 Illustration of APOV Improvement (Patient Receiving XHANCE 372 µg BID) Week 24Baseline 7.0% Improvement Images reflect individual results and results and may not be representative of results generally.
Slide 21: Secondary Endpoints and Subgroup Analysis
21 Secondary Endpoints and Subgroup Analysis Top‐line results are limited: full analysis is still ongoing Four defining symptoms of Chronic Sinusitis ‐ XHANCE‐ treated patients had statistically significant improvement over EDS‐placebo treated patients on each of the four symptoms (congestion, rhi
Slide 22: AEs Occurring in ≥3% of Patients and More Common Than Placebo
22 AEs Occurring in ≥3% of Patients and More Common Than Placebo Adverse Event (AE) EDS‐placebo BID (N =112) n (%) XHANCE 186 mcg BID (N =111) n (%) XHANCE 372 mcg BID (N =109) n (%) Epistaxis 1 (0.9) 5 (4.5) 13 (11.9) Nasopharyngitis 3 (2.7) 6 (5.4) 3 (2.8) Asthma 1 (0.9) 5 (4.5) 4 (3.7) Nuclear Ca
Slide 23: Additional Phase 3b Clinical Trial Data Expected in Q2 22
23 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top‐line results presented in Q1 2022 Top‐line results expected in Q2 2022 ReOpen1 ClinicalTrials.gov Identifier: NCT03781804 Enrolled 332 patients with CS of which 205
Slide 24: Additional Financial Information
Additional Financial Information
Slide 25: XHANCE Net Revenue per Prescription
25 XHANCE Net Revenue per Prescription $198 $185 $219 2019 2020 2021 ($ ) XHANCE Net Revenue per Prescription XHANCE net revenue per prescription ($/TRx) increased 11% from 2019 to 2021 In response to the COVID‐19 pandemic, Optinose offered the XHANCE ASSIST program in Q2 and Q3 2020 Commercia
Slide 26: XHANCE Gross Margin and Consistent R&D plus SG&A Expense
26 XHANCE Gross Margin Percentage and Consistent R&D plus SG&A Expense Has Enabled Revenue Growth to Translate to Decreasing Operating Loss ($000s) 2019 2020 2021 XHANCE Net Revenue 30,401 48,357 73,652 Licensing Revenues 4,230 750 1,000 Total Revenues 34,631 49,117 74,652 Cost of Product Sales 5,29
Slide 27: Full Year 2022 Financial Guidance
27 Full Year 2022 Financial Guidance XHANCE Net Revenue ‒ Expected to be at least $90 million XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $210 Operating Expense (GAAP) ‒ Expected to be between $135 – $140 million; approximately $10 million of which represents stock
Slide 28: Investor Relations
28 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 Investors@optinose.com At 31 December 2021: – $111 million in cash – Long‐term debt: $130 million – 82.2 million common shares o/s – 12.4 million options, warra
Slide 29: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n Ma r c h 8 , 2 0 2 2
Slide 30: Key Takeaways and Q4 2021 Highlights
30 Key Takeaways and Q4 2021 Highlights Consistent Commercial Execution Driving Q4 2021 Growth FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in 1Q2022 +44% XHANCE Net Revenue Growth Q4 2021/Q4 2020 $240 XHANCE Net Revenue per TRx in Q4 20